Citations

Clear

2 citation(s) found for "Schmidt, Christoph F".

Nucleotide-free structures of KIF20A illuminate atypical mechanochemistry in this kinesin-6
Ranaivoson, F.M. , Crozet, Vincent , Benoit, Matthieu P. M. H. , Khalid, Amna Abdalla Mohammed, Kikuti, Carlos , Sirkia, Helena , Marjou, Ahmed El , Miserey‐Lenkei, Stéphanie , Asenjo, Ana B. , Sosa, Hernando , Rosenfeld, Steven S. , Houdusse, Anne , Ranaivoson, Fanomezana Moutse , El Marjou, Ahmed , Schmidt, Christoph F , Rosenfeld, Steven S , Houdusse, Anne

Mayo Clinic

Open Biology | September 19, 2023 | Volume: 13 | Issue: 9 | Pages: No page available

10.1098/rsob.230122 | PMID 37726093 Get It

KIF20A is a critical kinesin for cell division and a promising anti-cancer drug target. The mechanisms underlying its cellular roles remain elusive. Interestingly, unusual coupling between the nucleotide- and microtubule-binding sites of this kinesin-6 has been reported, but little is known about how its divergent sequence leads to atypical motility properties. We present here the first high-resolution structure of its motor domain that delineates the highly unusual structural features of this motor, including a long L6 insertion that integrates into the core of the motor domain and that drastically affects allostery and ATPase activity. Together with the high-resolution cryo-electron microscopy microtubule-bound KIF20A structure that reveals the microtubule-binding interface, we dissect the peculiarities of the KIF20A sequence that influence its mechanochemistry, leading to low motility compared to other kinesins. Structural and functional insights from the KIF20A pre-power stroke conformation highlight the role of extended insertions in shaping the motor's mechanochemical cycle. Essential for force production and processivity is the length of the neck linker in kinesins. We highlight here the role of the sequence preceding the neck linker in controlling its backward docking and show that a neck linker four times longer than that in kinesin-1 is required for the activity of this motor.
High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P 3 Lysophospholipid Receptor
Theilmeier, Gregor , Schmidt, Christoph , Herrmann, Jörg, Keul, Petra , Schäfers, Michael , Herrgott, Ilka, Mersmann, Jan , Larmann, Jan , Hermann, Sven , Stypmann, Jörg, Schober, Otmar, Hildebrand, Reinhard, Schulz, Rainer , Heusch, Gerd , Haude, Michael , Lipinski, Karin von Wnuck, Herzog, Christine , Erbel, Raimund, Chun, Jerold , Levkau, Bodo , Schmitz, Martina

Mayo Clinic

Circulation | September 19, 2006 | Volume: 114 | Issue: 13 | Pages: 1403-1409

10.1161/circulationaha.105.607135 | PMID 16982942 Get It

Background— All treatments of acute myocardial infarction are aimed at rapid revascularization of the occluded vessel; however, no clinical strategies are currently available to protect the heart from ischemia/reperfusion injury after restitution of blood flow. We hypothesized that some of the cholesterol transport–independent biological properties of high-density lipoprotein (HDL) implied in atheroprotection may also be beneficial in settings of acute myocardial reperfusion injury. Methods and Results— In an in vivo mouse model of myocardial ischemia/reperfusion, we observed that HDL and its sphingolipid component, sphingosine-1-phosphate (S1P), dramatically attenuated infarction size by ≈20% and 40%, respectively. The underlying mechanism was an inhibition of inflammatory neutrophil recruitment and cardiomyocyte apoptosis in the infarcted area. In vitro, HDL and S1P potently suppressed leukocyte adhesion to activated endothelium under flow and protected rat neonatal cardiomyocytes against apoptosis. In vivo, HDL- and S1P-mediated cardioprotection was dependent on nitric oxide (NO) and the S1P 3 lysophospholipid receptor, because it was abolished by pharmacological NO synthase inhibition and was completely absent in S1P 3 -deficient mice. Conclusions— Our data demonstrate that HDL and its constituent, S1P, acutely protect the heart against ischemia/reperfusion injury in vivo via an S1P 3 -mediated and NO-dependent pathway. A rapid therapeutic elevation of S1P-containing HDL plasma levels may be beneficial in patients at high risk of acute myocardial ischemia.